Article
Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma.
JAMA dermatology - 1 Dec 2013
Busser Benoit, Leccia Marie Therese, Gras-Combe Guillaume, Bricault Ivan, Templier Isabelle, Claeys Antoine, Richard Marie Jeanne, de Fraipont Florence, Charles Julie
Abstract excerpt
IMPORTANCE: There is an increasing interest in BRAF V600 mutations in melanomas and their associated sensitivity to vemurafenib, a BRAF inhibitor. However, physicians cannot find information in the literature about vemurafenib response for rare and/or atypical BRAF mutations. OBSERVATIONS: We describe the identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.